
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new form of a drug called eribulin for solid tumours. A is any cancer apart from
or
.
Researchers are looking for new ways to treat solid tumours that can’t be removed with surgery or have got worse despite other treatment. In this trial, they are looking at a new form of a drug called eribulin.
Eribulin is a type of chemotherapy that doctors already use to treat some types of cancer. In this new form, the drug has been wrapped up in a fatty covering called a liposome. This helps the drug to stay in the bloodstream longer, so that more of the drug may reach cancer cells.
The aims of the trial are to
You may be able to enter this trial if you
You cannot enter this trial if you
This phase 1 trial will recruit up to 96 people. The trial is in 2 parts.
In the 1st part of the trial, researchers are trying to find the highest safe dose of liposomal eribulin and the best way to give it. The first patients taking part will have a very low dose of liposomal eribulin. If they don’t have any serious side effects, the next patients will have a higher dose. And so on, until they find the best dose to give. This is called a dose escalation study.
Everybody taking part has eribulin through a drip into a vein. It takes at least an hour each time. There are different ways of having the drug. Depending on when you join the trial, you have it either
In the 2nd part of the trial, researchers want to learn more about the side effects of liposomal eribulin. Everybody joining this part of the trial will have the highest safe dose that was found in part 1. They will have one of the treatment plans above. The treatment plans that the researchers will look at in this part of the study will also depend on the results from part 1.
As long as they don’t have bad side effects, people joining either part of the trial can carry on having liposomal eribulin for as long as it helps them.
You see the trial team and have some tests before you start treatment. The tests include
You may also need to have a bone scan.
The trial team will ask your permission to get a sample of tissue that was removed when your cancer was first diagnosed or when you had surgery.
The first time you have liposomal eribulin, you stay in hospital overnight. If you join the 1st part of the trial, you will be asked to wear a small portable machine that records your heartbeat. This is called a . You wear it for 24 hours before you have your first dose of eribulin and for at least 24 hours afterwards.
The number of hospital visits you have during treatment will depend on which treatment plan you have. Everybody has regular physical examinations, blood tests and urine tests. You have a CT or MRI scan every 6 or 8 weeks (depending on your treatment plan).
When you finish treatment, you see the trial team a month later and have a physical examination, heart trace, blood tests and urine tests.
If you stop the trial treatment for any reason other than your cancer getting worse, you will be asked to carry on having a CT or MRI scan every 8 or 9 weeks (depending on the treatment plan you’ve been having) until your cancer starts getting worse or you start having another treatment.
As liposomal eribulin is a new form of the drug, there may be side effects we don’t know about yet. The most common side effects of the standard form of eribulin include
We have more information about the standard form of eribulin.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Malcolm Ranson
Eisai
Experimental Cancer Medicine Centre (ECMC)
Freephone 0808 800 4040
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”